2013
DOI: 10.1002/eji.201242691
|View full text |Cite
|
Sign up to set email alerts
|

Secreted aspartic proteases of Candida albicans activate the NLRP3 inflammasome

Abstract: In a recent report, we demonstrated that distinct members of the secreted aspartic protease (Sap) family of Candida albicans are able to induce secretion of proinflammatory cytokines by human monocytes, independently of their proteolytic activity and specific pH optima. In particular, C. albicans Sap2 and Sap6 potently induced IL-1β, TNF-α, and IL-6 production. Here, we demonstrate that Sap2 and Sap6 proteins trigger IL-1β and IL-18 production through inflammasome activation. This occurs via NLRP3 and caspase-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
97
1
1

Year Published

2014
2014
2021
2021

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 99 publications
(102 citation statements)
references
References 60 publications
3
97
1
1
Order By: Relevance
“…34,36,37,39,128 C. albicans are able to trigger proinflammatory cytokine IL-1b and IL-18 production via NLRP3 inflammasome in murine monocytes, macrophages and dendritic cells. 129 Consistently, downregulation of NLRP3 by RNA interference strongly reduced the secretion of bioactive IL-1b. 129 Pyroptosis is an inflammasome-mediated programmed cell death.…”
Section: Prrs Of Neutrophils and Monocytes/macrophagesmentioning
confidence: 83%
See 1 more Smart Citation
“…34,36,37,39,128 C. albicans are able to trigger proinflammatory cytokine IL-1b and IL-18 production via NLRP3 inflammasome in murine monocytes, macrophages and dendritic cells. 129 Consistently, downregulation of NLRP3 by RNA interference strongly reduced the secretion of bioactive IL-1b. 129 Pyroptosis is an inflammasome-mediated programmed cell death.…”
Section: Prrs Of Neutrophils and Monocytes/macrophagesmentioning
confidence: 83%
“…129 Consistently, downregulation of NLRP3 by RNA interference strongly reduced the secretion of bioactive IL-1b. 129 Pyroptosis is an inflammasome-mediated programmed cell death. In bone marrow-derived macrophages and murine J774 macrophages, NLRP3 can be triggered by C. albicans, leading to NLRP3-mediated pyroptosis.…”
Section: Prrs Of Neutrophils and Monocytes/macrophagesmentioning
confidence: 83%
“…Candida albicans and its components, the secreted aspartic proteases, and Aspergillus hyphae activate the NLRP3 inflammasome, and this is mediated through pathways involving both ROS generation and K 1 efflux. [88][89][90] In a study on the pathogenesis of osteoarthritis, hydroxyapatite crystals stimulated NLRP3 inflammasome activation through multiple pathways: ROS generation, lysosomal damage, and K 1 efflux. 91 Additionally, the anthracycline doxorubicin induces systemic inflammation associated with IL-1b release, mediated by NLRP3 inflammasome activation, which is controlled by co-treatment with ROS inhibitors or by cultivation of cells with high levels of extracellular K 1 .…”
Section: Molecular Mechanisms Of the Canonical Activation Of The Nlrpmentioning
confidence: 99%
“…complement, histatin, antibodies), allowing C. albicans to escape the host immune system. 32,33,39 Some past 40,41 and more recent 42 data suggest that Sap may induce inflammation and thus contribute to fungal pathogenicity by fostering, rather than evading, the host immune systems (see below).…”
Section: Secretory Aspartyl Proteinases and Candidal Vaginitismentioning
confidence: 99%
“…the Als3 adhesin, formulated with alum as adjuvant, and a dominant member of the aspartyl proteinase enzyme family, the Sap2, in a virosomal formulation. 39,75 Both vaccines show solid evidence of protection in rat and mouse models of vaginal infection by C. albicans although with a likely different mechanism of immunological protection. 30,74 Other anti-Candida vaccines, from attenuated strains of C. albicans 76 to a number of glycoconjugate of cell wall polysaccharides, 77 have also been shown to be immunogenic and protective in experimental animal models, although these, to my knowledge, have not yet been entered into clinical trials in humans.…”
Section: Vaccines Against Rvvcmentioning
confidence: 99%